Immune-Onc Therapeutics’ IO-202 Earns Orphan Drug Designation for CMML from US FDA
Immune-Onc Therapeutics, the Hangzhou-based subsidiary of US company Immune-Onc Therapeutics Inc., has announced that it...
Immune-Onc Therapeutics
Immune-Onc Therapeutics Partners with Roche for Phase Ib/II Study of IO-108 in Liver Cancer
Immune-Onc Therapeutics Inc., based in the U.S., is entering into a collaboration with Roche (SWX:...
Immune-Onc Therapeutics Completes $131 Million Series B Financing
US-headquartered Immune-Onc Therapeutics, Inc. has announced the successful completion of a Series B financing round...
BeiGene Partners with Immune-Onc for Clinical Development of Myeloid Checkpoint Inhibitors
China-based biotech BeiGene (HKG: 6160, SHA: 688235, NASDAQ: BGNE) has entered into a clinical study...